Drug intelligence / Profile preview

EZ Derm

Development stage: Unknown
Lead developer: Mölnlycke
Administration: Topical

Overview

EZ Derm is a porcine xenograft wound dressing derived from pig skin, specifically processed to serve as a biological skin substitute. Developed and manufactured by Mölnlycke Health Care, it is primarily indicated for the treatment of partial-thickness burns, donor sites, and other skin injuries. The product acts as a temporary wound covering that maintains a moist environment conducive to re-epithelialization and the growth of granulation tissue, while simultaneously reducing pain and fluid loss. It can also be utilized as a temporary cover prior to autografting or as a protective layer over meshed autografts. It is chemically cross-linked porcine fetal dermis and is categorized as a skin substitute and biological dressing.

Brand names: EZ Derm
Other names: Porcine xenograftPorcine skin dressing

Beyond the preview

Go deeper on EZ Derm.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EZ Derm.

Explore the full profile